The Organism Most Doctors Don’t Test For
If you have been dealing with chronic illness — whether it carries a diagnosis of Lyme disease, chronic fatigue syndrome, fibromyalgia, autoimmune disease, or unexplained cognitive decline — there is a significant probability that mycoplasma is involved. And there is an equally significant probability that no one has tested for it.
Mycoplasma are the smallest known self-replicating organisms. They are not quite bacteria, not quite viruses — they occupy a unique biological category that falls between conventional diagnostic boundaries. This in-between status is part of the reason they are so frequently missed. They do not grow on standard bacterial culture plates. They do not respond to the most commonly prescribed antibiotics. And they are not included in routine diagnostic panels for most of the diseases they contribute to.
At the Frequency Research Foundation, Dr. Jeff Sutherland has observed mycoplasma in over 80% of people tested — a finding consistent with other independent researchers in the field. Understanding mycoplasma is not a niche concern. It is central to understanding why so many chronic diseases persist despite treatment.
How Mycoplasma Work: The Cellular Mechanism
What makes mycoplasma uniquely dangerous is their method of survival. They are intracellular parasites — meaning they enter human cells and live inside them, using the cell’s own resources to survive and reproduce.
The Invasion Process
Mycoplasma enter individual cells and, depending on genetic predisposition, may target different tissues in different people. If the pathogen destroys cells in the brain, neurological disease may develop. If it invades and destroys cells in the lower bowel, conditions like Crohn’s colitis may follow. If it targets joint tissues, rheumatoid arthritis or other collagen-vascular diseases may result.
This tissue-specific targeting explains one of the most puzzling aspects of mycoplasma-related illness: why the same organism produces such different diseases in different people. The answer lies in individual genetic predisposition and which tissues the mycoplasma infiltrate.
The Dormancy Problem
One of mycoplasma’s most challenging characteristics is their ability to lie dormant inside cells for extended periods — potentially 10, 20, or even 30 years. During dormancy, they cause no symptoms and are virtually undetectable. They can be triggered into active infection by trauma, surgery, vaccination reactions, severe stress, immune suppression, or co-infection with other pathogens.
This dormancy-activation pattern explains many cases of sudden-onset chronic illness in previously healthy individuals. A triggering event activates dormant mycoplasma, which then begins destroying host cells and provoking immune responses that produce chronic symptoms.
How They Kill Cells
Because mycoplasma lack the organelles to process their own nutrients, they survive by uptaking pre-formed sterols (essential fats) from the host cell. They literally consume the cell from within. When the cell is depleted, it ruptures and its contents — including inflammatory debris and mycoplasma progeny — are dumped into the bloodstream. This triggers immune activation and inflammation, while the released mycoplasma invade new cells and repeat the cycle.
This mechanism explains the fluctuating, relapsing-remitting symptom pattern that is characteristic of mycoplasma-related illness. Periods of relative calm alternate with flare-ups as cycles of cellular invasion, destruction, and immune response repeat.
Mycoplasma and the Lyme Disease Complex
The Frequency Research Foundation’s most extensive clinical experience with mycoplasma involves its role in Lyme disease. Mycoplasma is not a secondary or minor component of Lyme — it is a key factor driving chronic symptoms.
Clinical Observations
Dr. Jeff Sutherland’s clinical experience has revealed several consistent patterns. Mycoplasma fermentans is present in virtually all Lyme infections observed at the Foundation. When mycoplasma fermentans is targeted with frequencies, it produces what appear to be Brucella infections — both organisms must be targeted together along with several other pathogens for effective treatment.
Lyme infections are found in over 80% of the people Dr. Sutherland tests, a finding consistent with other researchers working in this area. The mycoplasma component is typically the most persistent element of the Lyme complex, outlasting spirochetes and most co-infections.
Why Mycoplasma Make Lyme Chronic
Standard Lyme treatment targets Borrelia spirochetes. Even when these are successfully eliminated, mycoplasma continue to cycle through invasion, dormancy, and reactivation — producing the fatigue, cognitive symptoms, and immune dysfunction that characterize “chronic Lyme.”
Our companion article Mycoplasma – Why the Lyme Flu Goes On and On examines this persistence pattern in detail, including the complicating role of nanobacteria within mycoplasma and the Herxheimer reactions that occur during treatment. For our latest comprehensive Lyme treatment protocol, see Update: Lyme Frequencies Version 11.0.
The Disease Associations: Far Beyond Lyme
Research from multiple independent investigators has linked pathogenic mycoplasma to a remarkably wide range of chronic diseases. This is not speculative — it is documented by senior researchers at major institutions.
Key Research Citations
Dr. Shyh-Ching Lo, a senior researcher at the Armed Forces Institute of Pathology and one of America’s leading mycoplasma researchers, has documented Mycoplasma fermentans in patients with AIDS, cancer, chronic fatigue syndrome, Crohn’s colitis, type 1 diabetes, multiple sclerosis, Parkinson’s disease, Wegener’s disease, collagen-vascular diseases including rheumatoid arthritis, and Alzheimer’s disease. Dr. Lo holds a US patent on Mycoplasma fermentans isolated from patients.
Dr. Charles Engel of the US National Institutes of Health stated at an NIH meeting on February 7, 2000: “I am now of the view that the probable cause of chronic fatigue syndrome and fibromyalgia is the mycoplasma.”
Dr. Maurice Hilleman, who served as chief virologist for the pharmaceutical company Merck Sharp & Dohme, stated that this disease agent is now carried by the vast majority of people in North America and potentially most people worldwide.
The Common Thread
The common thread across all these diseases is chronic immune activation and inflammation driven by an intracellular pathogen that the immune system recognizes but cannot effectively eliminate. Different tissues are affected in different people, producing different diagnostic labels — but the underlying mechanism is the same.
This connects directly to our foundational article Eliminating Inflammation Is a Top Priority for Disease Prevention. Mycoplasma are one of the most important drivers of the chronic inflammation that underpins heart disease, cancer, neurodegenerative disease, and autoimmune conditions.
Mycoplasma and Alzheimer’s Disease
The neurodegenerative implications of mycoplasma infection deserve particular attention within our Alzheimer’s research.
The Brain Infiltration Pathway
Mycoplasma can cross the blood-brain barrier and establish infections within brain tissue. Once there, they trigger the same destructive cycle that occurs in other tissues — cell invasion, sterol depletion, cell rupture, inflammatory response — but in the brain, the consequences are devastating.
Chronic microglial activation in response to mycoplasma creates persistent neuroinflammation. Neuronal energy depletion from mycoplasma parasitism impairs cognitive function. The inflammatory debris from ruptured cells contributes to the toxic environment that promotes amyloid accumulation.
Mycoplasma as Part of the Infectious Theory of Alzheimer’s
Mycoplasma is one of several chronic infections now linked to Alzheimer’s disease. The broader pattern — documented in our complete guide to Alzheimer’s disease and frequency therapy — involves multiple pathogen types contributing to the neuroinflammatory cascade that produces Alzheimer’s pathology.
Herpes simplex virus DNA has been found in 90% of Alzheimer’s plaques, as documented in our article Alzheimer’s and Herpes Simplex Virus. Lyme spirochetes can directly invade brain tissue and trigger neuroinflammation. Mycoplasma add another layer of persistent, treatment-resistant infection that sustains the inflammatory environment.
For many Alzheimer’s patients, the disease may not have a single infectious cause but rather a combination of chronic infections — viral, bacterial, and mycoplasmal — each contributing to the neuroinflammatory burden. Addressing all of them is essential for a comprehensive treatment strategy.
Historical Context: The Origins of Pathogenic Mycoplasma
The question of how pathogenic mycoplasma became so widespread has been the subject of significant investigation. Researcher Donald W. Scott, MA, MSc, as president of the Common Cause Medical Research Foundation, compiled extensive documentation — drawing from US and Canadian government documents and peer-reviewed journals — suggesting that several mycoplasma strains were modified through biological warfare research programs dating from the 1940s onward.
According to Scott’s research, biological warfare programs in the United States, Canada, and Britain focused on weaponizing the Brucella bacterium, from which pathogenic mycoplasma were derived. Scott documented that these programs involved participation from the US Public Health Service, the CDC, and the NIH, and that the resulting organisms were tested on populations without informed consent.
These claims are supported by Scott’s collection of government documents, patents (including Dr. Lo’s US patent on Mycoplasma fermentans), and peer-reviewed publications from journals including the Journal of the American Medical Association, the New England Journal of Medicine, and the Canadian Medical Association Journal.
Whatever their precise origin, the clinical reality is that pathogenic mycoplasma are now ubiquitous and are contributing to chronic illness on a massive scale. Understanding how to detect and eliminate them is more immediately relevant than resolving the historical debate about their creation.
2026 Update: 20 Years of Advancement
Since this article was first published, understanding of mycoplasma’s role in chronic disease has advanced on multiple fronts.
Mainstream Recognition Is Growing
While mycoplasma remain underdiagnosed in conventional practice, the medical literature’s recognition of their role in chronic disease has expanded significantly. Mycoplasma are now acknowledged as potential contributors to a wider range of conditions than were recognized in 2005, and the mechanisms of intracellular parasitism and immune evasion are better understood.
The Microbiome Revolution
The explosion of microbiome research since 2005 has provided a broader framework for understanding how mycoplasma interact with other organisms in the body. Mycoplasma do not exist in isolation — they interact with the broader microbial ecosystem, and disruptions to the microbiome (from antibiotics, glyphosate, or other factors) can create conditions that favor mycoplasma proliferation.
Our article Glyphosate Alzheimer’s Disease: Could This Common Herbicide Increase Your Risk? covers how environmental toxins disrupt the microbial environment in ways that may favor pathogenic organisms like mycoplasma.
Frequency Protocol Refinement
The Frequency Research Foundation’s mycoplasma protocols have been refined extensively since 2005. Dr. Jeff Sutherland’s systematic approach now addresses a wider range of mycoplasma species and strains, accounts for the Brucella co-infections that emerge when mycoplasma fermentans is targeted, and manages the complex Herxheimer reactions that occur during treatment. The protocols are part of our comprehensive Lyme disease frequency protocol, Version 11.0.
Post-COVID Parallels
The COVID-19 pandemic created widespread awareness of post-infectious chronic illness. Long COVID symptoms — persistent fatigue, brain fog, immune dysfunction, chronic inflammation — closely mirror the symptom patterns of chronic mycoplasma infection. This parallel has made the medical community more receptive to the concept that organisms can persist after acute infection and drive chronic symptoms, opening doors for broader acceptance of mycoplasma’s role in chronic disease.
How Frequency Therapy Addresses Mycoplasma
Mycoplasma’s unique biology — no cell wall, intracellular residence, dormancy capability, multiple strains — demands an approach that conventional medicine is poorly equipped to provide. Frequency therapy offers distinct advantages for this particular organism.
Frequency Therapy’s Advantages Against Mycoplasma
Conventional antibiotics effective against mycoplasma (tetracyclines, macrolides, fluoroquinolones) face several limitations: they require months-long courses, they cannot reliably reach organisms inside host cells at therapeutic concentrations, and they cannot distinguish between mycoplasma strains.
Frequency therapy bypasses these limitations. Frequencies penetrate cell membranes and can reach intracellular organisms directly. Different frequencies can target different mycoplasma strains within the same treatment session. The approach can address the Brucella co-infections that emerge when Mycoplasma fermentans is disrupted. Nanobacteria within mycoplasma can be targeted as part of a sequential protocol.
The Clinical Approach
Dr. Jeff Sutherland’s approach to mycoplasma involves identifying which mycoplasma species and strains are present, targeting the mycoplasma and its associated Brucella component simultaneously, managing Herxheimer reactions through sequential treatment of internal co-infections, and supporting immune recovery as the infection burden is reduced.
This systematic, multi-organism approach reflects the clinical reality that mycoplasma infections are never simple, single-pathogen problems.
Chronic illness that won’t resolve? Mycoplasma may be the missing piece. Dr. Jeff Sutherland has over two decades of experience developing frequency protocols for mycoplasma and its co-infections. A paid consultation can identify whether mycoplasma is contributing to your symptoms and develop a targeted treatment plan. Book Your Consultation
Frequently Asked Questions
Take the Next Step
Mycoplasma is one of the most underdiagnosed and undertreated contributors to chronic illness worldwide. Whether your symptoms carry a label of Lyme disease, chronic fatigue, fibromyalgia, autoimmune disease, or cognitive decline, mycoplasma may be a key component driving the problem.
Dr. Jeff Sutherland has spent over 20 years developing frequency protocols specifically for mycoplasma and the complex co-infections that accompany them. A paid consultation is the most direct way to assess whether mycoplasma is a factor in your case.
Book Your Consultation with Dr. Jeff Sutherland
This article is part of our comprehensive Alzheimer’s resource library. Mycoplasma infections that infiltrate the brain contribute to the chronic neuroinflammation that drives Alzheimer’s progression. Read our complete guide to Alzheimer’s disease and frequency therapy for the full scope of research on infections, environmental toxins, nutritional strategies, and frequency-based treatment approaches.
© Frequency Research Foundation. This content is for educational and informational purposes only. It is not intended to diagnose, treat, cure, or prevent any disease. Always consult with qualified healthcare professionals regarding medical conditions.